Cancer - Vincerx Pharam, Inc.

Status:

Active, open to accrual

ClinicalTrials.gov:

NCT05712889

An open-label, multicenter Phase 1 study to characterize safety, tolerability, preliminary antitumor activity and pharmacokinetics of VIP236 monotherapy in subjects with advanced cancer

Drug

VIP236

Condition

Biliary tract cancers, breast cancer, cervical cancer, endometrial carcinoma, gastric cancer/gastroesophageal junction adenocarcinoma, NSCLC, ovarian cancer, pancreatic adenocarcinoma, small cell lung cancer, urothelial cancer.